Figure 8
From: BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer
β-hCG acts via TGFβRII in BRCA1 mutated breast cancer cells. (a) In silico analysis of interaction between β-hCG and TGFβRII. (b) Western blot of β-hCG and TGFβRII from samples immunoprecipitated with anti-β-hCG or anti-IgG antibody in HCC1937 and HCC1937/wt BRCA1. IgG was used as negative control. #1 and #2 represents the repetition of the experiment. (c) Western blot analysis of P-TGFβRII (Try 336) upon treating HCC1937 and HCC1937/wt BRCA1 cells with β-hCG. (d) Western blot analysis of Smad2/3, Cyclin D1 and PCNA upon supplementation of β-hCG in HCC1937 and MCF7. Right panel shows the quantification of the blot. (e) IHC analysis of TGFβRII and Phospho-Smad3 in the mouse skin tumor of BRCA1 floxed tumor tissue samples.
